Physician profile
David Lindsay
NPI 1548607757
$2,173.17
in general payments reported to CMS, 2019-2025
11 companies · $75.63 in 2025
The $75.63 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2021: $124 · 2022: $1,106 · 2023: $131 · 2024: $172 · 2025: $75.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,382.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.51 | 2019-2025 | Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $146.58 | 2019 | |
| Genentech USA, INC. | $140.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $96.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.30 | 2021-2022 | |
| Shire North American Group INC | $22.29 | 2019 | |
| Blueprint Medicines Corporation | $19.28 | 2022 | |
| Pharming Healthcare, INC. | $18.38 | 2024 | Ruconest |
| Phadia US INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.